Provided by Tiger Fintech (Singapore) Pte. Ltd.

Emergent BioSolutions

7.83
-0.1700-2.12%
Post-market: 7.890.0587+0.75%19:35 EDT
Volume:584.92K
Turnover:4.60M
Market Cap:417.74M
PE:3.10
High:8.02
Open:8.00
Low:7.80
Close:8.00
52wk High:12.73
52wk Low:4.02
Shares:53.35M
Float Shares:48.26M
Volume Ratio:0.62
T/O Rate:1.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.53
EPS(LYR):-3.5962
ROE:30.24%
ROA:5.03%
PB:0.78
PE(LYR):-2.18

Loading ...

Aptevo Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 12

Aptevo Therapeutics Reports Q2 2025 Net Loss of $6.2M, EPS at $8.40, Compared to $5.9M Loss and $1,236.96 EPS in Q2 2024

Reuters
·
Aug 11

Aptevo Therapeutics Inc expected to post a loss of $83.20 a share - Earnings Preview

Reuters
·
Aug 08

Emergent BioSolutions Files for Mixed Shelf Offering of Upto $250 Mln - Filing

THOMSON REUTERS
·
Aug 08

Emergent BioSolutions Q2 Adj. EPS $0.16 Beats $(0.72) Estimate, Sales $140.90M Beat $105.00M Estimate

Benzinga
·
Aug 07

Emergent BioSolutions Inc Outlook Q3 Total Revenues $180 Mln - $210 Mln

THOMSON REUTERS
·
Aug 07

Emergent BioSolutions Inc Outlook FY Total Revenues $765 Mln - $835 Mln

THOMSON REUTERS
·
Aug 07

Emergent BioSolutions Q2 Gross Margin 36%

THOMSON REUTERS
·
Aug 07

Emergent BioSolutions Q2 Adjusted Gross Margin 49%

THOMSON REUTERS
·
Aug 07

Emergent BioSolutions Reports Second Quarter 2025 Financial Results

GlobeNewswire
·
Aug 07

Emergent BioSolutions Inc expected to post a loss of 49 cents a share - Earnings Preview

Reuters
·
Aug 05

Aptevo Therapeutics Inc expected to post a loss of $83.20 a share - Earnings Preview

Reuters
·
Aug 04

Emergent BioSolutions Drops Amid Volume Spike, Last Down 5.8%

THOMSON REUTERS
·
Jul 29

New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox

GlobeNewswire
·
Jul 28

Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives

GlobeNewswire
·
Jul 28

Aptevo Therapeutics Inc. Conducted Annual Stockholder Meeting

Reuters
·
Jul 25

Emergent BioSolutions Inc. to Announce Second Quarter 2025 Financial Results

Reuters
·
Jul 15

Aptevo Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Dirk Huebner, SVP and CMO

Reuters
·
Jul 10

Emergent BioSolutions Shares Rise Over 6% After HHS Contract Modification

Dow Jones
·
Jul 09

Emergent BioSolutions Secures $51.9 Million Contract for Smallpox Treatment with U.S. Government

Reuters
·
Jul 09